Jan Törnell, Chairman of the Board

MD, PhD, Chairman. Former global Vice President Strategy, AstraZeneca Oncology & Infection. Professor, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden. Chairman of Glactone Pharma AB and LIDDS AB. He serves on the Board of Directors at Diaprost AB and NeuroVive Pharmaceuticals AB, and is an innovator at Trophea AB. Currently also Chief Medical Scientist at AQILION AB.

Anders Bjartell, Board member

MD, PhD FEBU, Professor in Urology, Skåne university Hospital, Malmö, Sweden. Assistant Dean Medical Faculty, Lund University. Appointed Professor in Clinical Urology and Senior Consultant at Skåne University Hospital in Malmö 2006. National principal investigator for several trials of new drugs in castration resistant prostate cancer and Head of the clinical trial unit at the Urology Department at the same hospital. He leads a research group in translational prostate cancer research with long term experience in prostate cancer biomarkers. His research also encompasses clinical projects on robotic surgery, imaging, and drug development. Participation in several EU-sponsored prostate cancer projects. Published nearly 200 peer reviewed articles.

Jeanette Folking, Board member

PhD, M.Sc. in Pharmacy, followed by Post-doc studies in the US. She has gained broad experience from key international positions as medical director, project manager for drug development and head of clinical trials in the pharma industry at Novartis, Perstop Pharma, Searle Scandinavia, Tigran Technlogies and the CDC. Currently she is Vice President, Chief Development Officer at AQILION AB and the Project Leader of Laccure AB. She is a board member of Glactone Pharma AB.

Rebecka Hellsten, Board member

PhD in experimental clinical pharmacology. Associate Professor in molecular medicine. Senior researcher at Division of Urological Cancer, Department of Translational Medicine, Lund University. Experience in in vitro and in vivo prostate cancer models with relevance to preclinical drug development. More than 10 years of experience in research on STAT3-signaling and inhibition.

Jacob Kaluski, Board member

M.Sc. (Pharm.) Solid experience from international marketing and drug development/clinical research. Leadership positions within Pharmacia, among others as Vice President and Business Manager for growth hormone. Former chairman of Jederstrom Pharmaceuticals. Co-founder of TKT-Europe-5S. Board member of Centogene AG, Glactone Pharma AB and Belina AB.


Martin Johansson, CEO

PhD, Associate Professor in organic chemistry. More than 15 years experience in medicinal chemistry and drug development. Previously Chief Scientific Officer Respiratorius AB, senior research scientist Medicinal Chemistry AstraZeneca Södertälje, Sweden. Broad competence and experience in organic synthesis, medicinal chemistry, preclinical development and drug discovery.

Scientific Advisory Board

Michael Atkins

Deputy Director of the Georgetown-Lombardi Comprehensive Cancer Center in Washington, DC and Professor of Oncology and Medicine (Hematology/Oncology) at Georgetown University School of Medicine, USA.

Hua Yu

PhD, Billy and Audrey L. Wilder Professorship in Tumor Immunology Co-leader, Cancer Immunotherapeutics Program, City of Hope, California, USA.

Norman J Maitland

PhD, Professor, Director Cancer Research Unit, University of York, UK.

Rolf Kiessling

Senior Professor of Experimental Oncology and Senior Consultant at the Oncology Clinic, Karolinska University Hospital, Solna, Sweden.